Streetbeat News

Price Targets

GS

Citigroup analyst Keith Horowitz maintains a Buy rating on Goldman Sachs Gr (NYSE:GS) but lowers the price target from $400 to $370.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 4:26 pm

ZFOX

Cantor Fitzgerald analyst Jonathan Ruykhaver reiterated an Overweight rating on ZeroFox Holdings (NASDAQ:ZFOX) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 4:25 pm

SRPT

Citigroup analyst Neena Bitritto-Garg maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) but lowers the price target from $204 to $161.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 4:25 pm

SRPT

Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $153 to $166.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 4:24 pm

SBUX

A whale has taken a bearish stance on Starbucks (NASDAQ:SBUX) with 81% of detected unusual options trades being bearish. Whales have been targeting a price range of $90 to $130 for Starbucks over the last 3 months. TD Cowen maintains an Outperform rating with a price target of $117, while Piper Sandler downgraded to Neutral with a price target of $107.

Portfolio Pulse from Benzinga Insights

June 23, 2023 | 4:24 pm

SRPT

Citigroup analyst Neena Bitritto-Garg maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $161 to $204.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 4:24 pm

CSGP

Citigroup analyst Peter Christiansen maintains a Buy rating on CoStar Gr (NASDAQ:CSGP) and raises the price target from $92 to $105.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 4:22 pm

BEP

Scotiabank analyst Robert Hope reinstates Brookfield Renewable (NYSE:BEP) with an Outperform rating and announces a $38 price target.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 4:18 pm

GBNXF

CIBC analyst Robert Catellier has upgraded Gibson Energy (OTC:GBNXF) from Neutral to Outperformer and raised the price target from C$25 to C$27.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 4:13 pm

MRNS

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Marinus Pharma (NASDAQ:MRNS) and maintained a $28 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 4:01 pm